CHE — Chemed Corporation

Chemed Corporation (CHE) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• VITAS Healthcare:

  • Net revenue: $407.7 million, up 4.2% year-over-year.
  • Average revenue per patient day: $205.08, a 2.98% increase from the prior year.
  • Adjusted EBITDA (excluding Medicare Cap): $70.4 million, down 3.8% year-over-year; EBITDA margin: 17.0%.

• Roto-Rooter:

  • Revenue: Increased 1.1% year-over-year.
  • Branch residential revenue: $150.9 million, up 3.4%; commercial revenue: $55 million, up 2.8%.
  • Adjusted EBITDA: $49.4 million, down 12.4% year-over-year; EBITDA margin: 22.7%.

2. Strategic Updates and Business Highlights

• VITAS successfully managed Florida Medicare Cap billing limitations, achieving a billing limit of $18.9 million, slightly better than the estimated $19 million.
• Hospital admissions for VITAS reached 44.5%, indicating a strong focus on hospital-based admissions, which is crucial for long-term stability.
• Roto-Rooter saw an increase in residential plumbing revenue by 8.2%, attributed to targeted marketing campaigns.
• The new Pinellas County location for VITAS is set to open in early November, with expectations for growth in the Marion County program.

3. Forward Guidance and Outlook

• Management reiterated full-year guidance of $22 to $22.30 per share, excluding noncash expenses.
• VITAS is expected to have a strong fourth quarter, traditionally its best, with anticipated margin improvements due to new Medicare rates.
• Roto-Rooter is projected to benefit from seasonal weather conditions, which typically increase job volume in the colder months.

4. Bad News, Challenges, or Points of Concern

• Roto-Rooter’s revenue from independent contractors declined by 4.7%, indicating challenges in that segment.
• Adjusted EBITDA margins for both segments fell below long-term expectations, with Roto-Rooter margins particularly under pressure due to increased marketing costs.
• There are concerns regarding the sustainability of lead generation, with a noted shift from unpaid to paid leads, which could impact margins.

5. Notable Q&A Insights

• Management acknowledged that the slight underperformance in Q3 results compared to market expectations was due to seasonal trends and reaffirmed confidence in achieving guidance for Q4.
• Discussions highlighted the importance of managing the mix of hospital admissions to improve profitability, with a focus on balancing short-stay and long-stay patients.
• There were concerns about elevated Days Sales Outstanding (DSO), primarily attributed to timing issues with Medicaid payments, but management reassured that collection efforts remain strong.
• The competitive landscape for Roto-Rooter appears to be stabilizing, with management noting a reduction in competitive pressures for paid leads, which could enhance future margins.

Overall, Chemed Corporation demonstrated resilience in its operations, with strategic initiatives in place to address challenges while maintaining a positive outlook for the upcoming quarters.